Fraser Stephanie, Shih Judy Y, Ware Mark, O'Connor Edward, Cameron Mark J, Schwickart Martin, Zhao Xuemei, Regnstrom Karin
Pfizer, Eastern Point Rd, Groton, Connecticut, 06340, USA.
Amgen Inc., One Amgen Center Drive, Thousand Oaks, California, 91320, USA.
AAPS J. 2017 May;19(3):682-691. doi: 10.1208/s12248-017-0067-7. Epub 2017 Mar 20.
Numerous advances in ligand binding assay (LBA) real-time measurement technologies have been made within the last several years, ranging from the development of novel platforms to drive technology expansion to the adaptation of existing platforms to optimize performance and throughput. In this review, we have chosen to focus on technologies that provide increased value to two distinct segments of the LBA community. First, experimentally, by measuring real-time binding events, these technologies provide data that can be used to interrogate receptor/ligand binding interactions. While overall the platforms are not new, they have made significant advances in throughput, multiplexing, and/or sensitivity. Second, clinically, these point-of-care (POC) technologies provide instantaneous information which facilitates rapid treatment decisions.
在过去几年中，配体结合分析（LBA）实时测量技术取得了诸多进展，从推动技术扩展的新型平台开发到对现有平台进行优化以提升性能和通量。在本综述中，我们选择聚焦于为LBA领域两个不同细分领域带来更高价值的技术。首先，在实验方面，通过测量实时结合事件，这些技术提供的数据可用于探究受体/配体结合相互作用。虽然总体而言这些平台并非全新的，但它们在通量、多重分析和/或灵敏度方面取得了显著进展。其次，在临床方面，这些即时检测（POC）技术提供即时信息，有助于快速做出治疗决策。
